Cronos: The New Dawn is Bloober Team's best original game yet. An immersive romp through a suffocating portrayal of 80s ...

Like any great horror game, Cronos: The New Dawn will ignite fear and suspicion in you from its opening screen. Just when you ...

AT SIX. AND NEW AT SIX. A KITESURFER RESCUED OFF GRAVES LIGHT AND A CHANCE ENCOUNTER SAVED HIS LIFE. LET’S GET TO NEWSCENTER 5 JOHN ATWATER. HE SPOKE WITH HIM. HE JOINS US LIVE FROM EAST BOSTON RIGHT ...

Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...

SANTA MONICA, Calif. & PHILADELPHIA, August 21, 2025--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Kite-Surf event in Northern Germany Defender GKA Kite-Surf World Cup 2025 August 26th - 31th 2025, Sylt (GER) The GKA Kite World Tour returns to the legendary shores of Sylt in 2025 for an ...

More than 55 international kite flyers from 25 countries joined local enthusiasts The skies above Sri Lanka’s capital came alive in a dazzling display of colour as the Colombo International Kite ...

Kite will acquire Interius BioTherapeutics for $350 million, expanding into in vivo CAR T therapies. The deal is expected to cut Gilead’s 2025 EPS by 23-25 cents per share. Special Access: Get Market ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all the ...

Aug 21 (Reuters) - Gilead Sciences' (GILD.O), opens new tab unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance ...

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. California CAR-T company Appia Bio has closed up shop, founding CEO JeenJoo “JJ” Kang, Ph.D., wrote in an ...